Back to Search
MAX PALATNIK, M.D.
M.D.
Emergency Medicine Physician
NPI: 1821431644Individual
Specialties, Licenses & Credentials
Emergency Medicine PhysicianPrimary
Emergency Medicine
Code: 207P00000X
2016-00834(NC)
Research & Publications (20)
Decrease of the incidence of human and canine visceral leishmaniasis after dog vaccination with Leishmune in Brazilian endemic areas.
PMID 19464528·Vaccine·2009
7-preclinical
Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune vaccine.
PMID 17630055·Vaccine·2007
7-preclinical
Assessment of the monoterpene, glycidic and triterpene-moieties' contributions to the adjuvant function of the CP05 saponin of Calliandra pulcherrima Benth during vaccination against experimental visceral leishmaniasis.
PMID 17014936·Vaccine·2007
7-preclinical
Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis.
PMID 16556475·Vaccine·2006
7-preclinical
The mutation G298A-->Ala100Thr on the coding sequence of the Duffy antigen/chemokine receptor gene in non-caucasian Brazilians.
PMID 16110438·Genet Mol Res·2005
8-other
Pulcherrimasaponin, from the leaves of Calliandra pulcherrima, as adjuvant for immunization in the murine model of visceral leishmaniasis.
PMID 15620480·Vaccine·2005
4-observational
Improving methods for epidemiological control of canine visceral leishmaniasis based on a mathematical model. Impact on the incidence of the canine and human disease.
PMID 15334256·An Acad Bras Cienc·2004
7-preclinical
Protective vaccination against murine visceral leishmaniasis using aldehyde-containing Quillaja saponaria sapogenins.
PMID 15193411·Vaccine·2004
7-preclinical
Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine.
PMID 15149782·Vaccine·2004
7-preclinical
A novel blood group B subgroup: serological and genetic studies.
PMID 15113382·Transfus Med·2004
5-case
Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine.
PMID 14585674·Vaccine·2003
4-observational
IgG1/IgG2 antibody dichotomy in sera of vaccinated or naturally infected dogs with visceral leishmaniosis.
PMID 12744895·Vaccine·2003
7-preclinical
Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis.
PMID 12443660·Vaccine·2002
7-preclinical
Ethnicity and type 2 diabetes in Rio de Janeiro, Brazil, with a review of the prevalence of the disease in Amerindians.
PMID 12371680·Hum Biol·2002
8-other
Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante, RN).
PMID 12213397·Vaccine·2002
3-trial
Analysis of the -1185A/G von Willebrand factor (VWF) gene polymorphism in two Brazilian ethnic groups and its effect on the plasma VWF levels.
PMID 12091053·Thromb Res·2002
8-other
Impact of canine control on the epidemiology of canine and human visceral leishmaniasis in Brazil.
PMID 11716106·Am J Trop Med Hyg·2001
7-preclinical
Occurrence of Leishmania donovani parasitemia in plasma of infected hamsters.
PMID 11495646·Acta Trop·2001
7-preclinical
Genetic relationships between Amerindian populations of Argentina.
PMID 11385600·Am J Phys Anthropol·2001
8-other
Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani.
PMID 11312005·Vaccine·2001
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1313 21ST AVE S, 703 OXFORD HOUSE
NASHVILLE, TN 37232 - Phone
- (615) 936-0087
Quick Facts
- NPI
- 1821431644
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile